March 9, 2021

Feasibility Arrangement for Shelf-stable Powder Form of Messenger RNA COVID-19 Vaccine Candidate Announced by GreenLight Biosciences and TFF Pharmaceuticals

March 5, 2021

TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021

March 4, 2021

TFF Pharmaceuticals Provides Update on Clinical Development Programs

February 24, 2021

TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2020 Financial Results and Business Results Conference Call on March 10, 2021

February 19, 2021

TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

February 12, 2021

TFF Pharmaceuticals to Present at the BIO CEO & Investor Digital Conference

January 7, 2021

TFF Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

December 15, 2020

TFF Pharmaceuticals Announces First Dosing of Asthma Patients with Voriconazole Inhalation Powder in a Phase 1b Clinical Trial

November 12, 2020

TFF Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

November 5, 2020

TFF Pharmaceuticals Reports Third Quarter 2020 Financial and Business Results